Literature DB >> 10692488

Inhibition of c-myc expression in cells by targeting an RNA-protein interaction using antisense oligonucleotides.

C M Coulis1, C Lee, V Nardone, R D Prokipcak.   

Abstract

Antisense oligodeoxynucleotides (ODNs) are designed to bind to and inhibit a target mRNA. We used a novel approach for the design of ODNs to the c-myc mRNA using protein binding sites as targets for ODN action. Our strategy was to identify ODNs that could interfere with the coding region determinant-binding protein (CRD-BP), a protein that binds to the CRD region of the c-myc mRNA. Using an in vitro gel shift assay, we show that ODN molecules can occlude the CRD-BP from the mRNA. The best ODN, CRD-ODN4, was able to inhibit RNA binding of the CRD-BP by 75%. This effect was sequence-specific and concentration dependent. K562 cells treated with a 2'-O-methyl derivative of CRD-ODN4 showed a concentration-dependent decrease in both c-myc mRNA and protein levels, with a maximal 65% inhibition of protein expression at 200 nM CRD-ODN4. In contrast, a 2'-O-methyl ODN derivative targeting the translation initiation codon (antimyc-aug) reduced c-myc protein but actually increased mRNA levels, an effect resulting at least partly from stabilization of the c-myc mRNA. CRD-ODN4 treatment did not alter the c-myc mRNA half-life. CRD-ODN4 was more effective in inhibiting K562 cell growth than antimyc-aug, reducing cell number by approximately 70% after 48 h of exposure to 750 nM. The correlation between ODN effects on RNA-protein interactions in vitro and those observed in cells supports the hypothesis that CRD-ODN4 inhibits the interaction between the CRD-BP and the c-myc mRNA and that disrupting this RNA-protein interaction reduces c-myc expression in cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692488     DOI: 10.1124/mol.57.3.485

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Allele-specific conditional destabilization of glutamine repeat mRNAs.

Authors:  Andrew B Crouse; Peter J Detloff
Journal:  Gene Expr       Date:  2005

2.  Molecular insights into the coding region determinant-binding protein-RNA interaction through site-directed mutagenesis in the heterogeneous nuclear ribonucleoprotein-K-homology domains.

Authors:  Mark Barnes; Gerrit van Rensburg; Wai-Ming Li; Kashif Mehmood; Sebastian Mackedenski; Ching-Man Chan; Dustin T King; Andrew L Miller; Chow H Lee
Journal:  J Biol Chem       Date:  2014-11-11       Impact factor: 5.157

3.  IGF2BP1 enhances HCV IRES-mediated translation initiation via the 3'UTR.

Authors:  Susan Weinlich; Stefan Hüttelmaier; Angelika Schierhorn; Sven-Erik Behrens; Antje Ostareck-Lederer; Dirk H Ostareck
Journal:  RNA       Date:  2009-06-18       Impact factor: 4.942

4.  Alterations of renal phenotype and gene expression profiles due to protein overload in NOD-related mouse strains.

Authors:  Karen H S Wilson; Richard A McIndoe; Sarah Eckenrode; Laurence Morel; Anupam Agarwal; Byron P Croker; Jin-Xiong She
Journal:  BMC Nephrol       Date:  2005-12-21       Impact factor: 2.388

5.  CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease.

Authors:  Dan Sparanese; Chow H Lee
Journal:  Nucleic Acids Res       Date:  2007-01-30       Impact factor: 16.971

6.  Characterizing the Coding Region Determinant-Binding Protein (CRD-BP)-Microphthalmia-associated Transcription Factor (MITF) mRNA interaction.

Authors:  Gerrit van Rensburg; Sebastian Mackedenski; Chow H Lee
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

7.  Upregulation of Myc promotes the evasion of NK cell‑mediated immunity through suppression of NKG2D ligands in K562 cells.

Authors:  Young-Shin Lee; Woong Heo; Cheol-Hun Son; Chi-Dug Kang; You-Soo Park; Jaeho Bae
Journal:  Mol Med Rep       Date:  2019-08-09       Impact factor: 2.952

8.  Assessing specific oligonucleotides and small molecule antibiotics for the ability to inhibit the CRD-BP-CD44 RNA interaction.

Authors:  Dustin T King; Mark Barnes; Dana Thomsen; Chow H Lee
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.